文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

当代血液系统恶性肿瘤造血细胞移植中人类白细胞抗原错配与生存的关系

Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies.
PubMed 文献 · J Clin Oncol · 2024-08-21

该研究纳入2016至2020年间主要为急性白血病或相关髓系肿瘤的17,292例无关供者造血细胞移植(其中1,523例采用移植后环磷酰胺预防移植物抗宿主病),评估HLA错配与总生存的关联;HLA错配者总生存较低(HR 1.23),主要由I类HLA-A、HLA-B、HLA-C驱动(HR 1.29),而II类HLA-DRB1和HLA-DQB1未见显著关联(HR 1.07)。

要点

  • HLA错配移植总生存低于全合移植(HR 1.23,99%CI 1.14-1.33,P<.001)。
  • I类抗原水平错配及I类移植物抗宿主肽结合基序错配与更差总生存相关。
  • 移植后环磷酰胺预防下HLA错配增加死亡的风险与非移植后环磷酰胺移植相似(交互作用P=.43)。

核心结论

  • I类而非II类HLA错配,尤其是抗原水平和肽结合基序水平的错配,与当代无关供者造血细胞移植较差生存相关。
  • 这些效应在非移植后环磷酰胺与移植后环磷酰胺移植之间无显著差异。
  • 在现代造血细胞移植中仍应考虑优化HLA配型。

研究设计与样本

  • 研究纳入17,292例无关供者造血细胞移植,均具有6位点高分辨率HLA分型,主要针对2016至2020年间急性白血病或相关髓系肿瘤,其中1,523例移植采用移植后环磷酰胺。
  • 采用多因素Cox回归模型评估HLA风险关联,以总生存为主要终点。

主要发现

  • HLA错配移植总生存低于全合移植(HR 1.23,99%CI 1.14-1.33,P<.001)。
  • 该关联由I类HLA-A、HLA-B、HLA-C驱动(HR 1.29,99%CI 1.19-1.41,P<.001),而II类HLA-DRB1和HLA-DQB1未见显著关联(HR 1.07,99%CI 0.93-1.23,P=.19)。
  • I类抗原水平错配较等位基因水平错配总生存更差(HR 1.36,99%CI 1.24-1.49,P<.001)。
  • I类移植物抗宿主肽结合基序错配较匹配总生存更差(HR 1.42,99%CI 1.28-1.59,P<.001)。

关键数值与推荐

  • HLA错配与全合移植比较:总生存HR 1.23(99%CI 1.14-1.33,P<.001)。
  • I类HLA-A、HLA-B、HLA-C错配:HR 1.29(99%CI 1.19-1.41,P<.001)。
  • II类HLA-DRB1和HLA-DQB1错配:HR 1.07(99%CI 0.93-1.23,P=.19)。
  • I类抗原水平错配较等位基因水平错配:HR 1.36(99%CI 1.24-1.49,P<.001)。
  • I类移植物抗宿主肽结合基序错配较匹配:HR 1.42(99%CI 1.28-1.59,P<.001)。

临床怎么用

  • 作者认为,在现代造血细胞移植中仍应考虑优化HLA配型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSEHuman leukocyte antigen (HLA) mismatching can reduce survival of patients with blood cancer after hematopoietic cell transplantation (HCT). How recent advances in HCT practice, in particular graft-versus-host disease (GVHD) prophylaxis by post-transplantation cyclophosphamide (PTCy), influence HLA risk associations is unknown.PATIENTS AND METHODSThe study included 17,292 unrelated HCTs with 6-locus high-resolution HLA typing, performed mainly for acute leukemia or related myeloid neoplasms between 2016 and 2020, including 1,523 transplants with PTCy. HLA risk associations were evaluated by multivariable Cox regression models, with overall survival (OS) as primary end point.RESULTSOS was lower in HLA mismatched compared with fully matched transplants (hazard ratio [HR], 1.23 [99% CI, 1.14 to 1.33]; P < .001). This was driven by class I HLA-A, HLA-B, HLA-C (HR, 1.29 [99% CI, 1.19 to 1.41]; P < .001) but not class II HLA-DRB1 and HLA-DQB1 (HR, 1.07 [99% CI, 0.93 to 1.23]; P = .19). Class I antigen-level mismatches were associated with worse OS than allele-level mismatches (HR, 1.36 [99% CI, 1.24 to 1.49]; P < .001), as were class I graft-versus-host peptide-binding motif (PBM) mismatches compared with matches (HR, 1.42 [99% CI, 1.28 to 1.59]; P < .001). The use of PTCy improved GVHD, relapse-free survival compared with conventional prophylaxis in HLA-matched transplants (HR, 0.77 [0.66 to 0.9]; P < .001). HLA mismatching increased mortality in PTCy transplants (HR, 1.32 [1.04 to 1.68]; P = .003) similarly as in non-PTCy transplants (interaction P = .43).CONCLUSIONClass I but not class II HLA mismatches, especially at the antigen and PBM level, are associated with inferior survival in contemporary unrelated HCT. These effects are not significantly different between non-PTCy compared with PTCy transplants. Optimized HLA matching should still be considered in modern HCT.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Arrieta-Bolaños E, Bonneville EF, Crivello P, et al. Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2024. PMID: 39167735. doi:10.1200/JCO.24.00582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。